Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 577

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 6
Chunk 577
---
 transparent procedure for setting remuneration policies for all directors and senior management of the group. Whilst the Board retains its power to determine the remuneration of non-executive directors, the responsibility for reviewing and determining the remuneration package of individual executive directors and senior management of the group is delegated to the Remuneration Committee. The Committee is authorized to obtain, at the company’s expense, external legal or other professional advice on any matters within its Terms of Reference.

2024 Goals
In 2024, this strategy delivered significant results to our operations. As described below, a considerable number of company goals were set and achieved in 2024 on our regulatory, clinical development, discovery research, manufacturing, commercial, financial, business development, organizational and sustainability operations. These included:
Regulatory goals. Filed regulatory submissions in China of sovleplenib for immune thrombocytopenia, of savolitinib in MET exon 14 skipping alteration lung cancer including for treatment-naïve patients, of savolitinib with Tagrisso for EGFR TKI refractory lung cancer, of fruquintinib with sintilimab for EMC, and of tazemetostat for FL; obtained approval of fruquintinib with sintilimab for EMC in China, and of fruquintinib for CRC in the European Union and Japan. Also obtained fruquintinib approvals for CRC in Argentina, Australia, Canada, Hong Kong, Israel, Singapore, Switzerland, the United Arab Emirates, South Korea and the United Kingdom.
Clinical goals. Completed portfolio prioritization; enrolled first patients in the registration trials of ranosidenib for leukemia, sovleplenib for anemia, as well as the first patients enrolled in the HMPL-506 Phase I trial; completed enrollment in the registration trials of fanregratinib for intrahepatic cholangiocarcinoma, savolitinib combined with Tagrisso for lung cancer in the U.S., as well as the surufatinib Phase II trial for pancreatic cancer.
Discovery Research goals. Significant progress in developing the innovative ATTC platform, including several candidates nominated and in pre-clinical development and more to be nominated in the near-term.
Manufacturing goals. Streamlined operations across drug substance, drug product and manufacturing and supply chain; developed new Shanghai factory including passing the regulatory certification, obtaining the manufacturing license and delivering the first commercial batch of a key product ahead of schedule, and installing additional